Therapeutic Solutions International Inc (TSOI) 0.0065

New Post Public Reply Private Reply Replies (0) Message Board

Jul 31, 2016 at 8:12 AM

Therapeutic Solutions International Inc (TSOI) 0.0065 $TSOI

Therapeutic Solutions International Reports Augmentation of Cancer Immunotherapy Using Pterostilbene
Marketwire Canada - Mon Jul 11, 8:02AM CDT
OCEANSIDE, CA--(Marketwired - July 11, 2016) - Therapeutic Solutions International, Inc., (OTC PINK: TSOI) reported novel data supporting the use of pterostilbene, a natural analog of resveratrol with greater bioavailability, as an adjuvant to immunotherapy of cancer in a murine melanoma model. The reported data, which is part of the Company's filed Utility Patent #15/204560, demonstrated a synergy of inhibiting melanoma growth between pterostilbene and a T cell activating a FDA approved immunotherapeutic, as well as augmentation of immune stimulating cytokines. Cytokines are molecular signals the immune system uses to coordinate attacks on pathogenic invaders as well as cancer cells.

Therapeutic Solutions International Announces New Liposomal Products
Marketwire Canada - Wed Jun 22, 8:02AM CDT
OCEANSIDE, CA--(Marketwired - June 22, 2016) - Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today the addition of four new consumer products to our nutraceutical division.

Therapeutic Solutions International's Subsidiary MolecuVax, Inc. Announces Licensing of "Universal Cancer Vaccine" With Demonstrated Efficacy in Breast Cancer
Marketwired - Mon May 09, 8:02AM CDT
Clinical Stage Immunotherapy Company Expands Its Intellectual Property Portfolio by Exclusive Licensing of Issued Patents

Therapeutic Solutions International Files Patent Covering ProJuvenol(C) and Its Active Ingredient Pterostilbene
Marketwired - Thu Apr 28, 8:02AM CDT
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering the use of ProJuvenolÂ© and its active ingredient pterostilbene for augmentation of stem cell activity. Diseases such as diabetes(1), cardiovascular disease(2), and neurodegenerative diseases(3) are characterized by deficient stem cell activity. The patent covers the stimulation of stem cells that already exist in the patient's body, as well as stem cells that are administered therapeutically.

Therapeutic Solutions International's Subsidiary MolecuVax, Inc. to Initiate Cancer Immunotherapy Clinical Trial Aimed at Eradicating Cancer Stem Cells Using MVAX-001
Marketwired - Mon Apr 11, 8:02AM CDT
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an agreement between its subsidiary, MolecuVax, Inc., (MVAX) and the Pan Am Cancer Treatment Center covering production and clinical implementation of a novel cancer immunotherapy based around MVAX's proprietary Brother of the Regulator of Imprinted Sites (BORIS) peptide/exosome technology.

Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre
Marketwired - Mon Jan 25, 8:02AM CST
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an exclusive intellectual property license agreement with Gustave Roussy Transfert of Villejuif, France for an issued U.S. patent covering the clinically tested "Dexosome" cancer immunotherapy product.

Therapeutic Solutions International Announces the Appointment of BioPharmaceutical Pioneer Thomas E. Ichim, Ph.D to Board of Directors
Marketwired - Fri Jan 22, 8:00AM CST
Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the appointment of Dr. Thomas E. Ichim to our Board of Directors.

Therapeutic Solutions International Announces the Licensing of Probiotic Technology to OmniBiome, Inc.
Marketwired - Tue Dec 08, 7:55AM CST
Therapeutic Solutions International, Inc. (OTC PINK: TSOI) announced today that the Company has licensed an additional Patent to OmniBiome, Inc. (Omni), a wholly owned subsidiary of Therapeutic Solutions International, Inc., focused on Fetal-Maternal Health.

Therapeutic Solutions International Files Patent on Anticancer Nanotechnology Based Immunotherapy
Marketwired - Mon Nov 23, 7:55AM CST
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today a patent for developing a future generation of immune cell derived nanoparticles, termed exosomes, as a means of selectively stimulating the body's own natural defense mechanisms to seek and destroy cancer cells by company collaborators.

Therapeutic Solutions International Announces the Licensing of Patents to OmniBiome and the Appointment of Iryna Dzieciuch, M.S. as Chief Executive Officer of OmniBiome
Marketwired - Wed Nov 18, 7:55AM CST
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today that the Company has licensed three Patents to OmniBiome, Inc. ("OmniBiome"

a wholly owned subsidiary of Therapeutic Solutions International, Inc. ("TSI"

focused on Fetal-Maternal Health, with the Company's goal to assist women in the treatment or prevention of pre-term birth and pregnancy complications.

Therapeutic Solutions International Announces the Appointment of Michael G. Agadjanyan, Ph.D. to Company Scientific Advisory Board
Marketwired - Mon Oct 19, 7:55AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Michael Agadjanyan, Ph.D. has been appointed to our Scientific Advisory Board.

Therapeutic Solutions International Announces the Appointment of Harry M. Lander, Ph.D. to the TSI Scientific Advisory Board
Marketwired - Mon Oct 12, 7:55AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Harry M. Lander, Ph.D. has been appointed to our Scientific Advisory Board.

Therapeutic Solutions International, Inc. Announces the Appointment of Santosh Kesari, M.D., Ph.D. to Company Scientific Advisory Board
Marketwired - Tue Oct 06, 7:50AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today that Santosh Kesari, M.D., Ph.D., FANA, FAAN, has been appointed to our Scientific Advisory Board.

Therapeutic Solutions International Files Patent on Immune Therapy Medical Device to Prevent Preterm Labor
Marketwired - Tue Sep 29, 7:50AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announces the filing of U.S. Patent No. 62/232722 titled "A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth," covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor.

Therapeutic Solutions International Develops Cytokine Based Diagnostic Test for Preterm Labor and Complications of Pregnancy
Marketwired - Mon Sep 21, 8:00AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today the development of a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy associated complications.

Therapeutic Solutions International Announces Engagement With PLS CPA's
Marketwired - Tue Sep 15, 7:45AM CDT
Therapeutics Solutions International, Inc. (OTC PINK: TSOI) announced today the signing of an engagement with PLS CPA, A PC of San Diego CA. On September 10, 2015, Therapeutic Solutions International, Inc. (the "Company"

, approved the engagement of PLS CPA's ("PLS"

as the Company's independent registered public accounting firm beginning with the fiscal year ended December 31, 2013. The engagement of PLS has been approved by the Board of Directors of the Company on September, 10 2015.

Therapeutic Solutions International Files Patient on Cytokine Modulation to Prevent Pregnancy Loss and Pre-Term Labor
Marketwired - Tue Sep 08, 7:45AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering novel means of modulating the immune system to prevent miscarriages and preterm labor. The filed patent covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor. To the knowledge of the company, this is one of the only experimental approaches in development for addressing this unmet medical need.

Therapeutic Solutions International Files Patent on Cancer Immune Modulation Using Its ProJuvenol(TM) Product
Marketwired - Thu Jul 09, 7:30AM CDT
Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering the use of its ProJuvenol(TM) product, as well as various pterostilbene compositions, for use in augmenting efficacy of existing immuno-oncology drugs that are currently on the market. The patent is based on the ability of pterostilbene, one of the major ingredients of ProJuvenol(TM), to reduce oxidative stress produced by cancer cells, which in turn protects the immune system from cancer mediated immune suppression.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Vayo Debuts as Booking Holdings Eyes $100M Investment

A travel revolution might just be on the horizon, courtesy of Booking Holdings' latest venture, Vayo. And they’re talking about throwing $100 million into it—subject to a few conditions, sure—but that’s not pocket change you toss around without a serious plan. Transforming Travel into a Seamless Experience Vayo’s got one job: making your travels less like a...

FCS Drives Key FDA Approvals in Cancer Treatment

Florida Cancer Specialists: Changing the Cancer Treatment Game Some organizations toot their horns, but every now and then, a group truly shakes up the playing field. Take Florida Cancer Specialists & Research Institute (FCS), for instance. Over years of relentless research, FCS has nailed its role in securing two significant FDA approvals aimed at expanding treatment...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...